In addition, as depleting USP17 in NSCLC cells harboring EGFR activating mutations triggers their apoptosis, this indicates inhibiting USP17 may be of particular benefit in these tumors, which represent at least 10% of all NSCLC patients [17]. This evidence concerns the gene USP17L9P and non-small cell lung carcinoma.